2000至2020年疼痛药物临床开发项目成功概率分析
该研究基于Citeline数据库,估算2000年1月1日至2020年6月30日期间疼痛药物从I期到获批的成功概率、试验时长及存活率,并按试验阶段、疼痛类型(伤害性与神经病理性)及滥用潜力分层。结果显示所有疼痛药物总体成功概率为10.4%(标准误1.5%),伤害性疼痛与神经病理性疼痛药物分别为13.3%(标准误2.3%)与7.1%(标准误1.9%),高滥用潜力与低滥用潜力药物分别为27.8%(标准误4.6%)与4.7%(标准误1.2%),最常见的淘汰期在III期与获批之间。
要点
- 所有疼痛药物从I期到获批的总体成功概率为10.4%(标准误1.5%)。
- 伤害性疼痛药物成功概率13.3%(标准误2.3%),高于神经病理性疼痛的7.1%(标准误1.9%)。
- 高滥用潜力药物成功概率27.8%(标准误4.6%),低滥用潜力药物仅4.7%(标准误1.2%)。
核心结论
- 疼痛药物的滥用潜力和目标病理类型可影响其开发成功概率与开发时长。
研究设计与样本
- 利用Citeline数据库计算2000年1月1日至2020年6月30日间疼痛药物开发项目的成功概率、时长和存活率,并按阶段、疼痛类型和滥用潜力分层。
主要发现
- 所有疼痛药物从I期到获批的总体成功概率为10.4%(标准误1.5%)。
- 伤害性疼痛和神经病理性疼痛药物的成功概率分别为13.3%(标准误2.3%)和7.1%(标准误1.9%)。
- 高滥用潜力和低滥用潜力药物的成功概率分别为27.8%(标准误4.6%)和4.7%(标准误1.2%)。
- 最常见的淘汰期在III期与获批之间。
临床怎么用
- 麻醉科医生在参与疼痛药物研发或评估时,可参考不同疼痛类型和滥用潜力药物的成功概率差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The authors estimate the probability of successful development and duration of clinical trials for medications to treat neuropathic and nociceptive pain. The authors also consider the effect of the perceived abuse potential of the medication on these variables. METHODS: This study uses the Citeline database to compute the probabilities of success, duration, and survivorship of pain medication development programs between January 1, 2000, and June 30, 2020, conditioned on the phase, type of pain (nociceptive vs. neuropathic), and the abuse potential of the medication. RESULTS: The overall probability of successful development of all pain medications from phase 1 to approval is 10.4% (standard error, 1.5%). Medications to treat nociceptive and neuropathic pain have a probability of successful development of 13.3% (standard error, 2.3%) and 7.1% (standard error, 1.9%), respectively. The probability of successful development of medications with high abuse potential and low abuse potential are 27.8% (standard error, 4.6%) and 4.7% (standard error, 1.2%), respectively. The most common period for attrition is between phase 3 and approval. CONCLUSIONS: The authors' data suggest that the unique attributes of pain medications, such as their abuse potential and intended pathology, can influence the probability of successful development and duration of development.
引用
- Maher DP, Wong CH, Siah KW, et al. Estimates of Probabilities of Successful Development of Pain Medications: An Analysis of Pharmaceutical Clinical Development Programs from 2000 to 2020. Anesthesiology. 2022. PMID: 35504001. doi:10.1097/ALN.0000000000004265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。